John Carroll
Shares of Verastem cratered Wednesday morning as the Twitter crowd passed around an abstract on the company's defactinib (VS-6063), highlighting an extremely poor response rate for KRAS mutant non-small cell lung cancer.
-
Pfizer Wins Lyrica Patent Ruling 6 years ago 0
-
Mylan, Somaxon settle insomnia drug suit 6 years ago 0
-
Pertussis Rates Raise Questions About Vaccine 6 years ago 0
-
Buyers eye Relypsa and its hyperkalemia drug 3 years ago 0
-
Kenneth Bloom named president at Human Longevity 3 years ago 0
2013
after
announces
another
approval
AstraZeneca
biotech
buyout
cancer
China
clinical
data
deal
diabetes
drug
drugs
featured
first
from
gets
GlaxoSmithKline
Health
into
Lilly
market
Merck
more
Novartis
over
patent
Pfizer
Pharma
Pharmaceuticals
Phase
PhIII
Report
results
Roche
sales
Sanofi
says
study
trial
U.S.
UPDATED
Archives
- April 2016
- February 2016
- January 2016
- December 2015
- November 2015
- October 2015
- September 2015
- August 2015
- July 2015
- June 2015
- May 2015
- April 2015
- March 2015
- February 2015
- January 2015
- December 2014
- November 2014
- October 2014
- September 2014
- August 2014
- July 2014
- June 2014
- May 2014
- April 2014
- March 2014
- February 2014
- January 2014
- December 2013
- November 2013
- October 2013
- September 2013
- August 2013
- July 2013
- June 2013
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012